CrystalGenomics Inc
KOSDAQ:083790
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ecovyst Inc
NYSE:ECVT
|
US |
|
Motilal Oswal Financial Services Ltd
NSE:MOTILALOFS
|
IN |
CrystalGenomics Inc
Operating Income
CrystalGenomics Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CrystalGenomics Inc
KOSDAQ:083790
|
Operating Income
-₩23.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-20%
|
|
|
Celltrion Inc
KRX:068270
|
Operating Income
₩1.2T
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
17%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Operating Income
-₩123.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Operating Income
-₩36.3B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Operating Income
₩106.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
300%
|
CAGR 10-Years
97%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Operating Income
-₩40.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
CrystalGenomics Inc
Glance View
CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2006-01-06. The firm operates its business through four segments. The Drug Substance Manufacturing segment manufactures and sells drug substances such as anti-inflammatory analgesics, antispasmodics, and asthma treatments. The Finished Drug Manufacturing segment produces and supplies finished drugs such as cephalosporin antibiotics. The Pharmaceutical Research and Development segment is engaged in the provision of clinical trial analysis and technical services, and sales of new drugs. The company also engages in real estate rental business. The Other segment is engaged in the manufacture and sale of hot pats and other household goods.
See Also
What is CrystalGenomics Inc's Operating Income?
Operating Income
-23.8B
KRW
Based on the financial report for Dec 31, 2025, CrystalGenomics Inc's Operating Income amounts to -23.8B KRW.
What is CrystalGenomics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-20%
Over the last year, the Operating Income growth was 39%. The average annual Operating Income growth rates for CrystalGenomics Inc have been -1% over the past three years , -19% over the past five years , and -20% over the past ten years .
